Dimensional Fund Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Dimensional Fund Advisors’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-98,622	Closed	-$52K	–	3434
2019 Q4	$52K	Sell	98,622 -110,392	-53%	-$268K	﹤0.01%	3346
2019 Q3	$796K	Buy	209,014 +12,362	+6%	+$44.5K	﹤0.01%	3054
2019 Q2	$1.31M	Buy	196,652 +41,338	+27%	+$157K	﹤0.01%	2995
2019 Q1	$551K	Buy	155,314 +769	+0.5%	+$4.17K	﹤0.01%	3150
2018 Q4	$613K	Buy	154,545 +9,781	+7%	+$125K	﹤0.01%	3112
2018 Q3	$2.86M	Buy	144,764 +36,447	+34%	+$921K	﹤0.01%	2836
2018 Q2	$3.44M	Buy	108,317 +13,075	+14%	+$471K	﹤0.01%	2747
2018 Q1	$3.52M	Buy	95,242 +9,156	+11%	+$602K	﹤0.01%	2731
2017 Q4	$6.8M	Buy	+86,086	New	+$6.37M	﹤0.01%	2511

Dimensional Fund Advisors's MLNT Position: Q1 2020 in Review

Dimensional Fund Advisors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 98,622 shares — an estimated $52K sold.

Dimensional Fund Advisors first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $6.8M in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Dimensional Fund Advisors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Dimensional Fund Advisors sold 98,622 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $52K.
Dimensional Fund Advisors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Dimensional Fund Advisors's Melinta Therapeutics, Inc. Common Stock position peaked at $6.8M in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Dimensional Fund Advisors's 13F filing for Q1 2020, filed 14 May 2020.